Read by QxMD icon Read

Blood Cancer Journal

Sihem Tarfi, Véronique Harrivel, Florent Dumezy, Julien Guy, Mikael Roussel, Aguirre Mimoun, Pierre Fenaux, Nicolas Chapuis, Eric Solary, Dorothée Selimoglu-Buet, Orianne Wagner-Ballon
Peripheral blood monocytes include three subsets defined by CD14 and CD16 surface markers. An increase in the CD14++ CD16- classical monocyte fraction ≥ 94% of the total monocytes was proposed to rapidly and efficiently distinguish chronic myelomonocytic leukemia from reactive monocytosis. The robustness of this assay required a multicenter validation. The flow cytometry assay designed to quantify peripheral blood monocyte subsets was implemented by multiple diagnosis laboratories in France. A nationwide survey was performed to evaluate its performance...
November 14, 2018: Blood Cancer Journal
Jason Yongsheng Chan, Alvin Yu Jin Ng, Chee Leong Cheng, Maarja-Liisa Nairismägi, Byrappa Venkatesh, Daryl Ming Zhe Cheah, Shao-Tzu Li, Sock Hoai Chan, Joanne Ngeow, Yurike Laurensia, Jing Quan Lim, Jane Wan Lu Pang, Sanjanaa Nagarajan, Tammy Song, Burton Chia, Jing Tan, Dachuan Huang, Yeow Tee Goh, Eileen Poon, Nagavalli Somasundaram, Miriam Tao, Richard Hong Hui Quek, Mohamad Farid, Chiea Chuen Khor, Jin-Xin Bei, Soo Yong Tan, Soon Thye Lim, Choon Kiat Ong, Tiffany Tang
No abstract text is available yet for this article.
November 12, 2018: Blood Cancer Journal
Ulrike Bacher, Evgenii Shumilov, Johanna Flach, Naomi Porret, Raphael Joncourt, Gertrud Wiedemann, Martin Fiedler, Urban Novak, Ursula Amstutz, Thomas Pabst
Given the vast phenotypic and genetic heterogeneity of acute and chronic myeloid malignancies, hematologists have eagerly awaited the introduction of next-generation sequencing (NGS) into the routine diagnostic armamentarium to enable a more differentiated disease classification, risk stratification, and improved therapeutic decisions. At present, an increasing number of hematologic laboratories are in the process of integrating NGS procedures into the diagnostic algorithms of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs)...
November 12, 2018: Blood Cancer Journal
Valerio De Stefano, Elena Rossi, Alessandra Carobbio, Arianna Ghirardi, Silvia Betti, Guido Finazzi, Alessandro M Vannucchi, Tiziano Barbui
We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous thrombosis (935/565), pooling three independent cohorts previously reported. Long-term treatment with antiplatelet drugs or vitamin K-antagonists (VKA) was given to 1391 (92.7%) patients; 975 (65%) patients received hydroxyurea (HU). We recorded 348 recurrences (venous in 142 cases) over 6075 patient-years, with an incidence rate of 5.7 per 100 pt-years (95% CI 5.1-6.4). The site of the first thrombosis predicted the site of recurrence...
November 12, 2018: Blood Cancer Journal
Jing Jing Han, Megan O'byrne, Mary J Stenson, Matthew J Maurer, Linda E Wellik, Andrew L Feldman, Ellen D McPhail, Thomas E Witzig, Mamta Gupta
Peripheral T cell lymphomas (PTCL) is a heterogenous group of non-Hodgkin lymphoma and many patients remain refractory to the frontline therapy. Identifying new prognostic markers and treatment is an unmet need in PTCL. We analyzed phospho-STAT3 (pSTAT3) expression in a cohort of 169 PTCL tumors and show overall 38% positivity with varied distribution among PTCL subtypes with 27% (16/59) in PTCL-NOS; 29% (11/38) in AITL, 57% (13/28) in ALK-negative ALCL, and 93% in ALK-pos ALCL (14/15), respectively. Correlative analysis indicated an adverse correlation between pSTAT3 and overall survival (OS)...
November 12, 2018: Blood Cancer Journal
Paul G Richardson, Jesus F San Miguel, Philippe Moreau, Roman Hajek, Meletios A Dimopoulos, Jacob P Laubach, Antonio Palumbo, Katarina Luptakova, Dorothy Romanus, Tomas Skacel, Shaji K Kumar, Kenneth C Anderson
Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or long-term therapy. However, these therapies and approaches may have limitations in the community setting, associated with toxicity burden, patient burden, and other factors including cost. Consequently, despite improvements in efficacy in the rigorously controlled clinical trials setting, the same results are not always achieved in real-world practice...
November 9, 2018: Blood Cancer Journal
Shebli Atrash, Myra Robinson, Daniel Slaughter, Amanda Aneralla, Taylor Brown, Jordan Robinson, Ami Ndiaye, Chelsea Sprouse, Qing Zhang, James T Symanowski, Reed Friend, Peter M Voorhees, Saad Z Usmani, Manisha Bhutani
No abstract text is available yet for this article.
November 8, 2018: Blood Cancer Journal
A Castellino, A Chiappella, B R LaPlant, L D Pederson, G Gaidano, W R Macon, G Inghirami, C B Reeder, A Tucci, R L King, A Congiu, J M Foran, V Pavone, C E Rivera, M Spina, S M Ansell, F Cavallo, A L Molinari, Giovannino Ciccone, T M Habermann, T E Witzig, U Vitolo, G S Nowakowski
Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials, conducted by Mayo Clinic (MC) and Fondazione Italiana Linfomi (FIL). All patients received R-CHOP21 plus lenalidomide. Long-term progression-free survival (PFS), time to progression (TTP), overall survival (OS) and late toxicities and second tumors were analyzed...
November 8, 2018: Blood Cancer Journal
Sylvia Faict, Joséphine Muller, Kim De Veirman, Elke De Bruyne, Ken Maes, Louise Vrancken, Roy Heusschen, Hendrik De Raeve, Rik Schots, Karin Vanderkerken, Jo Caers, Eline Menu
Progression of multiple myeloma (MM) is largely dependent on the bone marrow (BM) microenvironment wherein communication through different factors including extracellular vesicles takes place. This cross-talk not only leads to drug resistance but also to the development of osteolysis. Targeting vesicle secretion could therefore simultaneously ameliorate drug response and bone disease. In this paper, we examined the effects of MM exosomes on different aspects of osteolysis using the 5TGM1 murine model. We found that 5TGM1 sEVs, or 'exosomes', not only enhanced osteoclast activity, they also blocked osteoblast differentiation and functionality in vitro...
November 8, 2018: Blood Cancer Journal
M Hasib Sidiqi, Mohammed A Aljama, Irbaz Bin Riaz, Angela Dispenzieri, Eli Muchtar, Francis K Buadi, Rahma Warsame, Martha Q Lacy, David Dingli, Nelson Leung, Wilson I Gonsalves, Prashant Kapoor, Taxiarchis V Kourelis, William J Hogan, S Vincent Rajkumar, Shaji K Kumar, Morie A Gertz
We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of 2017. Median age was 61 (interquartile range, 55-67) with 62% of patients being male. High-risk cytogenetic abnormalities (HRA) were present in 34% of patients. A total of 166 (68%) patients received some form of maintenance/other therapy post transplant (no maintenance (NM, n = 77), lenalidomide maintenance (LM, n = 108), bortezomib maintenance (BM, n = 39), and other therapy (OT, n = 19))...
November 8, 2018: Blood Cancer Journal
Tiziano Barbui, Guido Finazzi, Alessandro M Vannucchi, Valerio De Stefano
No abstract text is available yet for this article.
November 7, 2018: Blood Cancer Journal
Despina Fotiou, Theodoros N Sergentanis, Loula Papageorgiou, Kimon Stamatelopoulos, Maria Gavriatopoulou, Efstathios Kastritis, Theodora Psaltopoulou, Stella Salta, Patrick Van Dreden, Rabiatou Sangare, Annette K Larsen, Evangelos Terpos, Ismail Elalamy, Meletios A Dimopoulos, Grigoris T Gerotziafas
Venous thromboembolism (VTE) is a common complication in newly diagnosed symptomatic multiple myeloma (NDMM) patients. We explored cellular and plasma hypercoagulability in NDMM patients to identify relevant biomarkers that can be used in combination with clinical factors in the development of a risk assessment model (RAM) for VTE. Untreated patients (n = 144) with NDMM were prospectively enrolled, baseline biomarkers prior to anti-myeloma treatment and thromboprophylaxis initiation were obtained. These were compared against values in a group of healthy individuals with similar age and sex distribution...
November 7, 2018: Blood Cancer Journal
Guido Finazzi, Alessandro M Vannucchi, Tiziano Barbui
Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture is heterogeneous, ranging from isolated thrombocytosis, mimicking essential thrombocythemia (ET), to symptoms of high-risk PMF. Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF. Whilst a specific prognostic score is lacking, the International Prognostic Scoring System is able to predict survival in pre-PMF patients, yet failing to separate intermediate-1 and -2 groups, and can be used in clinical practice...
November 7, 2018: Blood Cancer Journal
Richa Manwani, Ute Hegenbart, Shameem Mahmood, Sajitha Sachchithanantham, Charalampia Kyriakou, Kwee Yong, Rakesh Popat, Neil Rabin, Carol Whelan, Tobias Dittrich, Christoph Kimmich, Philip Hawkins, Stefan Schönland, Ashutosh Wechalekar
High-dose melphalan with autologous stem cell transplantation (ASCT) can induce durable haematological and organ responses in systemic AL amyloidosis (AL). Stringent selection criteria have improved safety of ASCT in AL but most patients are transplant-ineligible. We report our experience of deferred ASCT in AL patients who were transplant-ineligible at presentation but had improvements in organ function after induction chemotherapy, enabling them to undergo ASCT. Twenty-two AL patients underwent deferred ASCT from 2011 to 2017...
November 5, 2018: Blood Cancer Journal
Ana Colado, Melanie Genoula, Céline Cougoule, José L Marín Franco, María B Almejún, Denise Risnik, Denise Kviatcovsky, Enrique Podaza, Esteban E Elías, Federico Fuentes, Isabelle Maridonneau-Parini, Fernando R Bezares, Horacio Fernandez Grecco, María Cabrejo, Carolina Jancic, María Del Carmen Sasiain, Mirta Giordano, Romina Gamberale, Luciana Balboa, Mercedes Borge
No abstract text is available yet for this article.
November 5, 2018: Blood Cancer Journal
Hiroko Nishida, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada
CD26, a 110-kDa transmembrane glycoprotein that is expressed on several tumor cells including malignant lymphoma, has been implicated in tumorigenesis: however, little is known regarding its role in multiple myeloma (MM). Recently, we identified CD26 expression on human osteoclasts (OCs) and demonstrated that humanized IgG1 monoclonal antibody targeting CD26, huCD26mAb, inhibits human OC differentiation. Herein, we show that CD26 expression was present on plasma cells in the bone marrow tissues of MM patients...
October 22, 2018: Blood Cancer Journal
George Z Rassidakis, Nikolas Herold, Ida Hed Myrberg, Nikolaos Tsesmetzis, Sean G Rudd, Jan-Inge Henter, Torsten Schaller, Siok-Bian Ng, Wee Joo Chng, Benedict Yan, Chin Hin Ng, Farhad Ravandi, Michael Andreeff, Hagop M Kantarjian, L Jeffrey Medeiros, Ioanna Xagoraris, Joseph D Khoury
Sterile alpha motif and histidine/aspartic acid domain containing protein 1 (SAMHD1) limits the efficacy of cytarabine (ara-C) used in AML by hydrolyzing its active metabolite ara-CTP and thus represents a promising therapeutic target. SAMHD1 has also been implicated in DNA damage repair that may impact DNA damage-inducing therapies such as anthracyclines, during induction therapy. To determine whether SAMHD1 limits ara-C efficacy during induction or consolidation therapy, SAMHD1 protein levels were assessed in two patient cohorts of de novo AML from The University of Texas MD Anderson Cancer Center (USA) and the National University Hospital (Singapore), respectively, using immunohistochemistry and tissue microarrays...
October 19, 2018: Blood Cancer Journal
Linda B Baughn, Kathryn Pearce, Dirk Larson, Mei-Yin Polley, Eran Elhaik, Michael Baird, Colin Colby, Joanne Benson, Zhuo Li, Yan Asmann, Terry Therneau, James R Cerhan, Celine M Vachon, A Keith Stewart, P Leif Bergsagel, Angela Dispenzieri, Shaji Kumar, S Vincent Rajkumar
Multiple myeloma (MM) is two- to three-fold more common in African Americans (AAs) compared to European Americans (EAs). This striking disparity, one of the highest of any cancer, may be due to underlying genetic predisposition between these groups. There are multiple unique cytogenetic subtypes of MM, and it is likely that the disparity is associated with only certain subtypes. Previous efforts to understand this disparity have relied on self-reported race rather than genetic ancestry, which may result in bias...
October 10, 2018: Blood Cancer Journal
Kerstin Wenzl, Michelle K Manske, Vivekananda Sarangi, Yan W Asmann, Patricia T Greipp, Hanna R Schoon, Esteban Braggio, Matthew J Maurer, Andrew L Feldman, Thomas E Witzig, Susan L Slager, Stephen M Ansell, James R Cerhan, Anne J Novak
MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between MYD88L265P and other genetic events is further supported by the fact that TNFAIP3 (A20) inactivation often accompanies MYD88L265P . However, we are still lacking information about the consequence of MYD88L265P in combination with TNFAIP3 loss in human B cell lymphoma. Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28% of WM, respectively...
October 9, 2018: Blood Cancer Journal
Emmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, Lydia Roy, Jerome Rey, Zineb Ghrieb, Robert Kralovics, Heinz Gisslinger, Barbara Grohmann-Izay, Christoph Klade, Christine Chomienne, Stéphane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian
Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden in interferon-treated patients, but significance of this observation is questioned. We characterized the activity of ropeginterferon alpha-2b, a novel form of interferon-alpha recently shown to be safe and efficacious in polycythemia vera. Ropeginterferon was able to inhibit the proliferation of the HEL, UKE-1, and UT-7 JAK2-mutant cell lines while sparing JAK2-wild-type UT-7 and normal CD34+ cells growth...
October 4, 2018: Blood Cancer Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"